Actinium Pharmaceuticals to Present at Biotech Showcase 2016

Press Releases |

Live Webcast on January 11, 2016 at 9:30 am PT

NEW YORK, NY--(January 11, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers, announced that the Company will be presenting at the 8th Annual Biotech Showcase today, Monday, January 11, 2016 at 9:30 am Pacific Time in Room Market Street. The Biotech Showcase is taking place on January 11 - 13, 2016 and is being held at the Parc 55 Hotel in San Francisco, California.

A live webcast of Actinium's presentation can be viewed via the following link that will also be on the Company's investor relations page http://edge.media-server.com/m/p/jjzeezy6.

Actinium's management will host one-on-one meetings with conference attendees at Biotech Showcase 2016, which can be scheduled through the partnering360® system.

http://www.ebdgroup.com/bts/index.php?source=apisrc_ebd_group&utm_source=EBD %20Group&utm_medium=web&utm_campaign=p1_clients .

Additional information on Biotech Showcase 2016 can be found here http://www.ebdgroup.com/bts/index.php.

About Actinium Pharmaceuticals



Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha -emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ATNM Actinium Pharmaceuticals Inc. (Delaware) 1.23 0.00 0.00 197,673

Comments

Emerging Growth

Blow & Drive Interlock Corp

Blow & Drive Interlock Corp manufactures, markets, leases, installs and monitors a Breath Alcohol Ignition Interlock Device mechanism on the steering column of an automobile and into which a driver…

Private Markets

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…

California Green Tree Development

California Green Tree Development LLC (CGTD) is a for-profit LLC that plans on using California’s booming market of legal cannabis products for medical purposes. As an unprecedented resource, Cannabis has…